Novamind Inc.

CSE: NM

Company Logo

Company Overview

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.

Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.

Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey.

Financial Highlights

$8,217,428

Revenue (ttm)

$3,399,354

Gross Profit (ttm)

-$0.23

Diluted EPS (ttm)

Management Team

Mr. Yaron Conforti
Co-Founder, CEO & Director

Mr. Jing Peng C.A., CPA
CFO & Corp. Sec.

Dr. Reid J. Robison M.D., MBA
Chief Medical Officer & Director

Mr. Prakash Gowd B.Sc., B.Sc. (Pharm), MBA
Chief Operating Officer

Dr. Paul Thielking M.D.
Chief Scientific Officer & Principal Investigator

Dr. Soni Rao Ph.D.
VP of Program, Services Devel., Quality & Compliance

Ms. Samantha DeLenardo
VP of Communications

Ms. Seneca Anderson
Sr. VP of Corp. Devel.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
32%